Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 5/20 | 0.70 |
| ▸ | RAB9A | P51151 | 5/20 | 0.70 |
| ▸ | MAPT | P10636 | 5/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.70 |
| ▸ | MEN1 | O00255 | 2/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.70 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.59 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.57 |
| ▸ | MDH1 | P40925 | 2/20 | 0.57 |
| ▸ | RXRA | P19793 | 1/20 | 0.56 |
| ▸ | RXRB | P28702 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | PLK1 | P53350 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9369169 | 0.91 | RAB9A (0.74) | NPC1RAB9AMAPTSMN1; SMN2MEN1 | |
| SCHEMBL11350421 | 0.88 | RAB9A (0.82) | NPC1RAB9AMAPTSMN1; SMN2MEN1 | |
| SCHEMBL10236929 | 0.88 | RAB9A (0.82) | NPC1RAB9AMAPTSMN1; SMN2MEN1 | |
| SCHEMBL1792416 | 0.88 | CYP4A11 (0.74) | NPC1RAB9AMAPTSMN1; SMN2CYP4A11 | |
| SCHEMBL21656841 | 0.87 | CYP4A11 (0.64) | NPC1RAB9AMAPTSMN1; SMN2MEN1 | |
| SCHEMBL12086470 | 0.86 | RAB9A (0.80) | NPC1RAB9AMAPTSMN1; SMN2MEN1 | |
| SCHEMBL7424382 | 0.86 | MAPT (0.64) | NPC1RAB9AMAPTSMN1; SMN2MEN1 | |
| SCHEMBL1123143 | 0.85 | RXRA (0.72) | NPC1RAB9ASMN1; SMN2RXRARXRB | |
| SCHEMBL7738901 | 0.85 | MAOB (0.68) | NPC1RAB9AMAPTSMN1; SMN2RXRA | |
| SCHEMBL7776764 | 0.85 | RAB9A (0.65) | NPC1RAB9AMAPTSMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1644321-B1 | NEW BENZAMIDES AS PPATY MODULATORS | S A L V A T LAB SA (ES) | 2011-02-09 | — | — | EP | disclosed |
| US-7754886-B2 | N-acylsulfonamide apoptosis promoters | ABBOTT LABORATORIES (US) | 2010-07-13 | — | — | US | disclosed |
| US-20090137585-A1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ABBOTT LABORATORIES (US) | 2009-05-28 | — | — | US | disclosed |
| US-7504512-B2 | N-acylsulfonamide apoptosis promoters | ABBOTT LABORATORIES (US) | 2009-03-17 | — | — | US | disclosed |
| US-20060160894-A1 | Benzamides as ppar modulators | LABORATORIOS S.A.L.V.A.T.,S.A. (ES) | 2006-07-20 | — | — | US | disclosed |
| EP-1644321-A2 | NEW BENZAMIDES AS PPATY MODULATORS | LABORATORIOS S.A.L.V.A.T., S.A. (ES) | 2006-04-12 | — | — | EP | disclosed |
| EP-1318978-B1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ABBOTT LAB (US) | 2006-02-08 | — | — | EP | disclosed |
| WO-2004110983-A2 | NEW BENZAMIDES AS PPARϒ MODULATORS | LABORATORIOS S.A.L.V.A.T., S.A. (ES) | 2004-12-23 | — | — | WO | disclosed |
| US-6720338-B2 | BCL-X1 INHIBITING COMPOSITIONS AND METHODS OF PROMOTING APOPTOSIS IN A MAMMAL | ABBOTT LABORATORIES | 2004-04-13 | — | — | US | disclosed |
| EP-1318978-A2 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | Abbott Laboratories (US) | 2003-06-18 | — | — | EP | disclosed |
| US-20020086887-A1 | N-Acylsulfonamide apoptosis promoters | ABBVIE INC. | 2002-07-04 | — | — | US | disclosed |
| US-20020055631-A1 | N-acylsulfonamide apoptosis promoters | ABBOTT LABORATORIES | 2002-05-09 | — | — | US | disclosed |
| WO-2002024636-A2 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ABBOTT LABORATORIES (US) | 2002-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020086887-A1 | N-Acylsulfonamide apoptosis promoters | BAX, BCLAF1, BCL2 | NPC1 2540/4885RAB9A 4211/4885MAPT 4851/4885 |
| US-20020055631-A1 | N-acylsulfonamide apoptosis promoters | BAX, BCLAF1, BCL2 | NPC1 2435/4885RAB9A 3769/4885MAPT 4830/4885 |
| US-20060160894-A1 | Benzamides as ppar modulators | PPARD, PPARA, PPARG | NPC1 3147/4885RAB9A 4567/4885MAPT 4365/4885 |
| US-20090137585-A1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | BAX, BCL2, BCOR | NPC1 3122/4885RAB9A 3753/4885MAPT 4806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.